

Jennifer G Goldman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7121/publications.pdf>

Version: 2024-02-01

77
papers

12,149
citations

87888

38
h-index

85541

71
g-index

79
all docs

79
docs citations

79
times ranked

10275
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Transcriptional analysis of peripheral memory T cells reveals Parkinson's disease-specific gene signatures. <i>Npj Parkinson's Disease</i> , 2022, 8, 30. | 5.3 | 20 |
| 2 | Level I <sc>PD&MCI</sc> Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 479-483. | 1.5 | 11 |
| 3 | Cognitive Syndromes Associated With Movement Disorders. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 726-749. | 0.8 | 0 |
| 4 | Twelve Drummers Drumming& With Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 6. | 2.0 | 3 |
| 5 | Huntington disease. , 2021, , 371-400.e14. | | 0 |
| 6 | Peripheral electrical stimulation to reduce pathological tremor: a review. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2021, 18, 33. | 4.6 | 27 |
| 7 | Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 124. | 6.2 | 1 |
| 8 | Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 367-382. | 6.1 | 21 |
| 9 | Nonmotor problems in Parkinson disease. , 2021, , 234-248.e7. | | 0 |
| 10 | Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. <i>Frontiers in Neurology</i> , 2021, 12, 805135. | 2.4 | 12 |
| 11 | Validation of an Online Screener, the Mediterranean Eating Pattern for Americans-III in Older Patients with Parkinson's Disease. <i>Journal of Nutrition in Gerontology and Geriatrics</i> , 2020, 39, 30-43. | 1.0 | 3 |
| 12 | The effects of dual-task cognitive interference on gait and turning in Huntington's disease. <i>PLoS ONE</i> , 2020, 15, e0226827. | 2.5 | 15 |
| 13 | Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 137. | 6.2 | 32 |
| 14 | Creating a patient-centered guide to navigating cognitive change in Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041115. | 0.8 | 0 |
| 15 | The complexity of DLB: U.S.-based Dementia with Lewy Body Consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, e042846. | 0.8 | 0 |
| 16 | Shared imaging biomarkers across Alzheimer's and Parkinson's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046542. | 0.8 | 1 |
| 17 | Integrated Care in Parkinson's Disease: A Systematic Review and <sc>Meta&Analysis</sc>. <i>Movement Disorders</i> , 2020, 35, 1509-1531. | 3.9 | 71 |
| 18 | Treatment of Nonmotor Symptoms Associated with Parkinson Disease. <i>Neurologic Clinics</i> , 2020, 38, 269-292. | 1.8 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Cognitive Impairment and Dementia in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 365-377. | 2.6 | 43 |
| 20 | Î±-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinsonâ€™s disease. <i>Nature Communications</i> , 2020, 11, 1875. | 12.8 | 239 |
| 21 | Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, 743-755. | 1.1 | 365 |
| 22 | Acceptability and Reliability of an Online Version of the MEPA III Screener IN Parkinsonâ€™s Participants (P01-010-19). <i>Current Developments in Nutrition</i> , 2019, 3, nzz028.P01-010-19. | 0.3 | 0 |
| 23 | Motor phenotype classification in moderate to advanced PD in BioFIND study. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 178-183. | 2.2 | 20 |
| 24 | Lewy Body Dementia Associationâ€™s Research Centers of Excellence Program: Inaugural Meeting Proceedings. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 23. | 6.2 | 9 |
| 25 | The Effects of Dualâ€¢Task Cognitive Interference and Environmental Challenges on Balance in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 202-212. | 1.5 | 24 |
| 26 | High-Spatial-Resolution Diffusion MRI in Parkinson Disease: Lateral Asymmetry of the Substantia Nigra. <i>Radiology</i> , 2019, 291, 149-157. | 7.3 | 35 |
| 27 | Risk of Parkinson's disease dementia related to level I MDS PDâ€™MCI. <i>Movement Disorders</i> , 2019, 34, 430-435. | 3.9 | 32 |
| 28 | Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018, 33, 499-500. | 3.9 | 2 |
| 29 | Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018, 33, 503-510. | 3.9 | 52 |
| 30 | Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. <i>Movement Disorders</i> , 2018, 33, 528-536. | 3.9 | 17 |
| 31 | Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 208-218. | 3.9 | 138 |
| 32 | White matter abnormalities in the corpus callosum with cognitive impairment in Parkinson disease. <i>Neurology</i> , 2018, 91, e2244-e2255. | 1.1 | 66 |
| 33 | Validation of a performanceâ€¢based assessment of cognitive functional ability in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1760-1768. | 3.9 | 17 |
| 34 | Detecting Mild Cognitive Deficits in <sc>P</sc>arkinson's <sc>D</sc>isease: <sc>C</sc>omparison of <sc>N</sc>europsychological <sc>T</sc>ests. <i>Movement Disorders</i> , 2018, 33, 1750-1759. | 3.9 | 42 |
| 35 | Cognitive impairment in Parkinsonâ€™s disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. <i>Npj Parkinson's Disease</i> , 2018, 4, 19. | 5.3 | 110 |
| 36 | Reply To: <sc>D</sc>etection of <sc>A</sc>lphaâ€¢Synuclein in <sc>S</sc>aliva: <sc>T</sc>he <sc>I</sc>mportance of <sc>P</sc>reanalytical <sc>A</sc>ssessment. <i>Movement Disorders</i> , 2018, 33, 1031-1031. | 3.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. <i>Movement Disorders</i> , 2018, 33, 282-288. | 3.9 | 122 |
| 38 | Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease. <i>Neurology</i> , 2017, 88, 1265-1272. | 1.1 | 71 |
| 39 | Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100. | 1.1 | 2,805 |
| 40 | Mild cognitive impairment as a risk factor for Parkinson's disease dementia. <i>Movement Disorders</i> , 2017, 32, 1056-1065. | 3.9 | 117 |
| 41 | Î±-synuclein genetic variability: A biomarker for dementia in Parkinson disease. <i>Annals of Neurology</i> , 2016, 79, 991-999. | 5.3 | 85 |
| 42 | Arguing against the proposed definition changes of PD. <i>Movement Disorders</i> , 2016, 31, 1619-1622. | 3.9 | 55 |
| 43 | Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 11-22. | 3.9 | 31 |
| 44 | The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. <i>Movement Disorders</i> , 2016, 31, 924-932. | 3.9 | 48 |
| 45 | Association of <i>GBA</i> Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 1217. | 9.0 | 185 |
| 46 | <i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102. | 3.9 | 158 |
| 47 | Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. <i>Movement Disorders</i> , 2015, 30, 1657-1663. | 3.9 | 143 |
| 48 | Diagnosing PD+MCI by MDS task force criteria: How many and which neuropsychological tests?. <i>Movement Disorders</i> , 2015, 30, 402-406. | 3.9 | 125 |
| 49 | Advances in the treatment of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1471-1489. | 3.9 | 65 |
| 50 | Functional Brain Activity Relates to 3 and 8 Hz Force Oscillations in Essential Tremor. <i>Cerebral Cortex</i> , 2015, 25, 4191-4202. | 2.9 | 67 |
| 51 | Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2015, 5, 425-443. | 2.2 | 28 |
| 52 | Writer's cramp. <i>Toxicon</i> , 2015, 107, 98-104. | 1.6 | 17 |
| 53 | Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. <i>Movement Disorders</i> , 2014, 29, 1252-1257. | 3.9 | 7 |
| 54 | Premotor and nonmotor features of Parkinson's disease. <i>Current Opinion in Neurology</i> , 2014, 27, 434-441. | 3.6 | 253 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. <i>Neurobiology of Disease</i> , 2014, 69, 1-14. | 4.4 | 56 |
| 56 | Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. <i>Brain</i> , 2014, 137, 849-859. | 7.6 | 135 |
| 57 | The spectrum of cognitive impairment in Lewy body diseases. <i>Movement Disorders</i> , 2014, 29, 608-621. | 3.9 | 107 |
| 58 | Treatment of Psychosis and Dementia in Parkinson's Disease. <i>Current Treatment Options in Neurology</i> , 2014, 16, 281. | 1.8 | 103 |
| 59 | Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1135-1139. | 2.2 | 38 |
| 60 | Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria. <i>Journal of Parkinson's Disease</i> , 2014, 4, 131-137. | 2.8 | 50 |
| 61 | Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable. <i>Journal of Parkinson's Disease</i> , 2014, 4, 585-589. | 2.8 | 15 |
| 62 | Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 806-811. | 2.2 | 64 |
| 63 | Clinical features of neurodegeneration with brain iron accumulation due to a <i>C19orf12</i> gene mutation. <i>Movement Disorders</i> , 2013, 28, 1462-1463. | 3.9 | 14 |
| 64 | Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1972-1979. | 3.9 | 110 |
| 65 | Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1129-1136. | 3.9 | 87 |
| 66 | Clinical validation of movement disorder society's recommended diagnostic criteria for Parkinson's disease with dementia. <i>Movement Disorders</i> , 2012, 27, 248-253. | 3.9 | 51 |
| 67 | Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012, 27, 349-356. | 3.9 | 1,908 |
| 68 | Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. <i>Movement Disorders</i> , 2012, 27, 727-734. | 3.9 | 49 |
| 69 | An update expert opinion on management and research strategies in Parkinson's disease psychosis. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2009-2024. | 1.8 | 42 |
| 70 | New Thoughts on Thought Disorders in Parkinson's Disease: Review of Current Research Strategies and Challenges. <i>Parkinson's Disease</i> , 2011, 2011, 1-12. | 1.1 | 11 |
| 71 | Racial differences may influence the role of cholecystikinin polymorphisms in Parkinson's disease hallucinations. <i>Movement Disorders</i> , 2011, 26, 1781-1783. | 3.9 | 15 |
| 72 | MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. <i>Movement Disorders</i> , 2011, 26, 1814-1824. | 3.9 | 649 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | A recommended scale for cognitive screening in clinical trials of Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2501-2507. | 3.9 | 155 |
| 74 | Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. <i>Movement Disorders</i> , 2008, 23, 2248-2250. | 3.9 | 81 |
| 75 | Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707. | 3.9 | 2,497 |
| 76 | Genetic Polymorphisms in Parkinson Disease Subjects With and Without Hallucinations. <i>Archives of Neurology</i> , 2004, 61, 1280-4. | 4.5 | 51 |
| 77 | Treatment of Dystonia. <i>Clinical Neuropharmacology</i> , 2003, 26, 102-108. | 0.7 | 29 |